Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.

European journal of haematology - 1 Mar 2016

Markiewicz Miroslaw, Dzierzak Mietla Monika, Wieczorkiewicz Agata, Mizia Sylwia, Helbig Grzegorz, Kopera Malgorzata, Bialas Krzysztof, Rybicka Malwina, Matyja Mariusz, Koclega Anna, Sedlak Lech, Oleksy Tomasz, Raman Sundar, Kyrcz-Krzemien Slawomira

Abstract excerpt

OBJECTIVES: We evaluated the safety and outcome of allo-HSCTs in myelofibrosis (MF). METHODS: A total of 27 patients with primary (n = 20) or secondary (n = 7) MF, aged 51 (21-63) yr, transplanted from HLA-matched related (59%) or unrelated (41%) donors were analyzed. Conditioning was reduced in 26 and myeloablative in one patient; and ATG was used in 25. Sources of stem cells were as follows: peripheral blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Graft vs Host Disease
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Primary Myelofibrosis

Share to Tissue Donors

Share to Transplantation, Homologous

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 25899468
DOI: 10.1111/ejh.12572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.PMID 25899468Read ↗

Allogeneic stem cell transplantation for myelofibrosis in 2012.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Semantic proximity Read ↗

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Semantic proximity Read ↗

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.Semantic proximity Read ↗

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.Semantic proximity Read ↗

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.Semantic proximity Read ↗

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysisSemantic proximity Read ↗

Controversies and dilemmas in allogeneic transplantation for myelofibrosis.Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMTSemantic proximity Read ↗

Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell TransplantationSemantic proximity Read ↗

Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.